Vontobel Holding Ltd. lowered its position in Tilray Inc (NASDAQ:TLRY) by 2.2% in the 1st quarter, according to its most recent 13F filing with the SEC. The firm owned 32,584 shares of the company’s stock after selling 716 shares during the period. Vontobel Holding Ltd.’s holdings in Tilray were worth $741,000 at the end of the most recent quarter.
A number of other institutional investors have also recently modified their holdings of the stock. Cambria Investment Management L.P. boosted its holdings in shares of Tilray by 42.3% during the 1st quarter. Cambria Investment Management L.P. now owns 43,068 shares of the company’s stock valued at $979,000 after purchasing an additional 12,804 shares during the last quarter. Oppenheimer & Co. Inc. bought a new position in shares of Tilray during the 1st quarter valued at about $741,000. Cambridge Investment Research Advisors Inc. boosted its holdings in shares of Tilray by 69.1% during the 1st quarter. Cambridge Investment Research Advisors Inc. now owns 51,850 shares of the company’s stock valued at $1,179,000 after purchasing an additional 21,181 shares during the last quarter. Sowell Financial Services LLC boosted its holdings in shares of Tilray by 4,776.0% during the 1st quarter. Sowell Financial Services LLC now owns 7,314 shares of the company’s stock valued at $103,000 after purchasing an additional 7,164 shares during the last quarter. Finally, Graypoint LLC bought a new position in shares of Tilray during the 1st quarter valued at about $589,000. 7.06% of the stock is owned by institutional investors.
Several research analysts have commented on TLRY shares. Cantor Fitzgerald raised shares of Tilray from a “neutral” rating to an “overweight” rating and dropped their price objective for the company from $30.25 to $22.00 in a report on Wednesday, June 2nd. Benchmark reaffirmed a “hold” rating on shares of Tilray in a report on Thursday, February 25th. Cowen started coverage on shares of Tilray in a report on Tuesday, May 11th. They issued an “outperform” rating for the company. CIBC downgraded shares of Tilray from an “outperform” rating to a “neutral” rating in a report on Thursday. Finally, Piper Sandler reaffirmed a “neutral” rating and issued a $26.00 price target (up previously from $15.00) on shares of Tilray in a report on Thursday, February 25th. Ten research analysts have rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and an average price target of $20.38.
Tilray stock opened at $20.05 on Friday. The company has a debt-to-equity ratio of 0.82, a current ratio of 1.91 and a quick ratio of 1.40. Tilray Inc has a 1-year low of $4.41 and a 1-year high of $67.00. The stock has a market cap of $8.97 billion, a price-to-earnings ratio of -7.43 and a beta of 2.64. The stock has a 50-day moving average price of $17.38.
Tilray (NASDAQ:TLRY) last issued its earnings results on Monday, May 10th. The company reported ($0.19) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.10) by ($0.09). The company had revenue of $48.02 million for the quarter, compared to analysts’ expectations of $61.86 million. Tilray had a negative return on equity of 51.07% and a negative net margin of 207.32%. On average, equities analysts predict that Tilray Inc will post -1.14 EPS for the current year.
Tilray, Inc engages in the research, cultivation, processing, and distribution of medical cannabis. The company offers its products in Argentina, Australia, Canada, Chile, Croatia, Cyprus, the Czech Republic, Germany, New Zealand, and South Africa. Tilray, Inc is headquartered in Nanaimo, Canada.
Featured Article: What is a Leveraged Buyout (LBO)?
Want to see what other hedge funds are holding TLRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Tilray Inc (NASDAQ:TLRY).
Receive News & Ratings for Tilray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tilray and related companies with MarketBeat.com's FREE daily email newsletter.